Loading stock data…
Picard Medical, Inc. (PMI)
$4.29-0.27 (-5.86%)
Market OpenUpdated 12:20 PM EDT
Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Picard Medical, Inc. in the Healthcare sector is trading at $4.31 with a market capitalization of $29M. The stock is currently near its 52-week low of $2.65, remaining 90.8% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.15M↑ | $1.01M↓ | $1.19M↓ | $2.13M↑ | $620,000 |
| Gross Profit | $275,000↓ | $411,000↑ | -$130,000↓ | -$127,000↑ | -$358,000 |
| Operating Income | -$4.51M↓ | -$3.00M↑ | -$3.49M↑ | -$3.52M↓ | -$3.25M |
| Net Income | -$7.62M↓ | -$4.29M↑ | -$10.43M↓ | -$6.72M↓ | -$5.56M |
Peer Comparison
JNJUNHPFE
Fundamentals
Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.71M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
2006.70%
Volume
Today's trading volume
111,027
Recent News
Altria vs. Philip Morris: What the New Manufacturing Deal Means for Investors
Altria Group, Inc. (NYSE:MO) and Philip Morris International Inc. (NYSE:PM) have entered into reciprocal contract manufacturing arrangements designed to improve manufacturing efficiency and expand their operational flexibility. The first shipments are expected in 2027, while both companies said the agreements are not expected to have a material impact on their 2026 results. The deal is […]
Picard Medical Shares Soar After Quarterly Revenue Beats Forecasts
Picard Medical Inc. (AMEX:PMI) shares surged nearly 43.
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates
Dare Bioscience (DARE) delivered earnings and revenue surprises of +39.39% and +1,775.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Philip Morris' IQOS Retains FDA Modified-Risk Authorization
Philip Morris wins renewed FDA backing for IQOS, keeping its modified-risk claims alive as the company accelerates its shift beyond cigarettes.
PMI Q4 Earnings Call Highlights
Precigen’s leadership team outlined rapid early commercialization progress for its recently approved therapy PAPZIMEOS during a Wednesday, March 25, 2026, update call covering fourth-quarter and full-year 2025 results. Management said the company has shifted from being primarily an R&D organizat